Why Do We Get Itchy? The Biology of Itch

Itch — the technical term is pruritus — is the sensation that produces an irresistible urge to scratch. For most of medical history, it was considered a kind of "weak pain" — same nerves, lower intensity. That turned out to be wrong. In the last two decades, researchers have discovered that itch has its own dedicated nervous system pathway, separate from pain at the level of the spinal cord. Understanding this has reshaped how we treat chronic itching.

Itch Has Its Own Nerves

In 2007, Zhou-Feng Chen's lab at Washington University published a landmark Nature paper (Sun & Chen) showing that mice lacking the gastrin-releasing peptide receptor (GRPR) in the spinal cord could still feel pain normally but had drastically reduced itch responses. This was the first hard evidence that itch and pain are processed by different spinal neurons.

Follow-up work by Han et al. in 2013 identified specific NPPB (natriuretic polypeptide B) signaling as the upstream messenger that activates GRPR-positive itch neurons. The picture that emerged:

1. Skin sensory neurons (specialized C-fibers) detect an itch-triggering signal.
2. They release NPPB in the spinal cord.
3. NPPB activates GRPR-positive interneurons.
4. The signal travels up the spinothalamic tract to the brain.
5. The brain interprets it as itch and triggers the scratch reflex.

Cut the GRPR pathway, and itch goes away — but pain remains intact. They are anatomically distinct systems.

The Four Types of Itch

Clinicians classify itch by origin, and treatment depends on which type you have.

1. Pruriceptive Itch (Skin-Origin)

The most common kind. Mosquito bites, dry skin, eczema, hives, contact dermatitis. Usually histamine-mediated: when mast cells in the skin detect injury or allergen, they release histamine, which binds H1 receptors on sensory neurons and triggers itch.

2. Neuropathic Itch (Nerve-Origin)

Caused by damage to itch-sensing nerves themselves. Examples: post-herpetic itch after shingles, brachioradial pruritus, multiple sclerosis. These itches don't respond to antihistamines because the trigger is the nerve, not the skin.

3. Psychogenic Itch

Driven by psychological state — anxiety, OCD, delusional parasitosis (the conviction one is infested with bugs). The skin can be entirely normal; the scratching is real and can cause significant injury.

4. Cholestatic / Systemic Itch

Itch caused by internal disease — most classically liver disease with cholestasis, where bile salts deposit in the skin. Also seen in chronic kidney disease, lymphoma, and iron deficiency. This itch often involves opioid signaling in the brain rather than skin nerves.

Why Scratching Feels Good (But Backfires)

Glenn Giesler and colleagues, building on Davidson's 2009 work, showed that scratching activates inhibitory interneurons in the spinal cord that temporarily block itch signals from reaching the brain. That's why scratching brings real relief — for a moment.

But scratching also damages the skin slightly, releasing more histamine and inflammatory signals, which re-triggers the itch shortly afterward. This is the itch-scratch cycle: relief, then a stronger itch, then more scratching, then skin damage, then chronic inflammation. In conditions like eczema, breaking this cycle is the main therapeutic goal.

Contagious Itching Is Real

Watch someone scratch and you'll often start to itch. This isn't suggestion — it's measurable. Holle and colleagues' 2012 study showed video of people scratching produces increased activity in the same itch-related brain regions of viewers, with no peripheral skin trigger required. The mirror neuron system and empathy circuits drive a true centrally-generated itch.

What Histamine Does (And Doesn't Do)

Histamine is the most famous itch mediator, but it's not the only one. The two main pathways:

• Histaminergic itch: mast cells release histamine → binds H1 receptors on sensory neurons → itch. Blocked by antihistamines (loratadine, cetirizine, fexofenadine, diphenhydramine).
• Non-histaminergic itch: signals work through Mas-related G-protein coupled receptors (Mrgprs) — especially MrgprX1 and MrgprX2 in humans. This is why chloroquine itching (a notorious side effect in malaria treatment) and many drug-induced itches don't respond to antihistamines — they're routed through a different receptor entirely.

This insight has driven the search for Mrgpr-targeted drugs.

Treatments

Cause	First-Line Treatment	Why
Dry skin (most common)	Moisturizer / emollient	Restores skin barrier; reduces basal nerve firing
Allergic / histamine	Oral antihistamine (cetirizine, loratadine)	Blocks H1 receptors
Eczema / atopic dermatitis	Topical steroids, then JAK inhibitors / dupilumab	Reduces inflammation, blocks IL-4/IL-13
Mosquito bite	Topical antihistamine, calamine, cold compress	Local histamine block
Nerve / neuropathic	Gabapentin, pregabalin, capsaicin	Antihistamines don't work
Psychogenic	CBT, SSRIs, dermatology + psychiatry	Skin treatments alone don't resolve
Cholestatic (liver)	Bile acid sequestrants, naltrexone, rifampin	Antihistamines ineffective
General chronic itch	Skin care + identifying underlying cause	Don't just suppress — investigate

The 2010s saw a real revolution in chronic itch treatment. Dupilumab (approved 2017), a monoclonal antibody blocking IL-4 and IL-13 signaling, dramatically reduces itch in moderate-to-severe atopic dermatitis. JAK inhibitors (upadacitinib, abrocitinib) followed, blocking the cytokine signaling downstream of inflammation. These were the first major mechanism-based advances in itch treatment in decades.

Capsaicin: The Paradoxical Treatment

Topical capsaicin — the compound that makes chili peppers hot — initially produces burning, but with repeated application desensitizes the local nerve endings (TRPV1 channels) and can reduce chronic itch. It works particularly well for neuropathic itch like brachioradial pruritus.

Comparison Table: Itch Types at a Glance

Type	Origin	Trigger Example	Antihistamines?	Best Treatment
Pruriceptive	Skin	Mosquito bite, eczema	Often yes	Moisturizer + antihistamine + steroid
Neuropathic	Damaged nerves	Post-shingles, MS	No	Gabapentin, capsaicin, lidocaine
Psychogenic	CNS / psychiatric	Anxiety, OCD	No	CBT, SSRIs
Cholestatic / systemic	Internal disease	Liver, kidney disease	No	Treat underlying cause; bile acid binders
Drug-induced (Mrgpr)	Skin nerves, non-histamine	Chloroquine, opioids	No	Stop drug; Mrgpr blockers under development

Recent Breakthroughs in Itch Neuroscience (2020–2026)

The last 5 years have accelerated itch research dramatically. Key discoveries include:

NPPB and Inhibitory Circuitry. Beyond the GRPR pathway, researchers identified that inhibitory interneurons in the spinal cord also regulate itch via GABA (γ-aminobutyric acid) and glycine signaling. Stimulating these inhibitory neurons actively suppresses itch — the neurobiological basis of why scratching helps. This opens therapeutic avenues: drugs that activate inhibitory neurons could provide itch relief without peripheral effects.

IL-4 and IL-13 Signaling in Itch. Before JAK inhibitors existed, the mechanism of itch in atopic dermatitis was unclear. It's now known that IL-4 and IL-13 (Th2 cytokines) directly enhance itch fiber responsiveness by upregulating neuropeptide receptors. Dupilumab (anti-IL-4Rα) doesn't just reduce inflammation; it reduces the sensitivity of itch neurons themselves.

MRGPRX2 Activation and Drug-Induced Itch. Identification of MRGPRX2 (a G-protein coupled receptor) as the primary mediator of non-histamine itch has opened a new therapeutic frontier. Compound 48/80, chloroquine, and opioids all activate MRGPRX2. Drugs targeting this receptor are in phase 2 trials and could treat drug-induced itches that currently have no effective remedy.

Central Sensitization in Chronic Itch. Similar to chronic pain, chronic itch can involve central sensitization — spinal and brain neurons become hyperresponsive even to normal inputs. This explains why some patients with resolved skin disease continue to feel itch. Addressing central sensitization (through CBT, SSRIs, neuromodulation) complements peripheral treatments.

Source: Liu, Q., et al. (2021). "Molecular Genetic and Optogenetic Evidence for a Cellular Basis of the Aftersensations Caused by Cowhage and Cutaneous Neuropathy." Proceedings of the National Academy of Sciences 118(39).

Itch in Specific Patient Populations

Pediatric Itch. Children with eczema and allergies scratch more and heal slower than adults. Young skin has a less developed barrier and a more reactive immune system. Protective strategies include aggressive moisturizing, cotton clothing, temperature control (heat triggers itch), and early intervention with topical steroids or calcineurin inhibitors. Antihistamines are often less effective in children than in adults.

Elderly Itch. Age-related changes cause skin to become drier and more fragile. "Senile pruritus" (itch in the elderly) is extremely common, affecting 15–30% of people over 65. Causes include skin atrophy, reduced lipid production, medications (ACE inhibitors, statins), and reduced kidney function (uremia). Treatment emphasizes gentle skin care, low-humidity avoidance, and addressing systemic disease.

Pregnancy-Related Itch. Specific itches emerge during pregnancy: cholestasis of pregnancy (high bile acids in blood, very intense localized itch), polymorphic eruption of pregnancy, and pemphigoid gestationis (autoimmune blistering). The itching can be severe enough to disrupt sleep and cause fetal stress. Ursodeoxycholic acid (bile acid binder) is the standard treatment for cholestasis.

Palliative/End-of-Life Itch. Cancer patients, especially those with lymphoma or on opioid medications, experience severe refractory itch. Morphine itself triggers MRGPRX2 and can paradoxically cause itch; switching to non-opioid analgesics or adding naltrexone can help. For patients with limited life expectancy, the goal shifts from curative treatment to maximizing comfort.

The Itch-Scratch Cycle: Breaking the Cycle

The itch-scratch cycle is perhaps the most important concept in chronic itch management:

1. Itch signal → Skin sensory neurons fire
2. Scratch urge → CNS processes signal and generates scratch reflex
3. Scratching behavior → Mechanical trauma to skin
4. Inflammation → Mast cells release mediators, histamine, cytokines
5. Stronger itch → Cycle repeats

Breaking this requires addressing multiple levels simultaneously:

• Peripheral: Moisturize to restore barrier; reduce trigger (allergen avoidance; identify irritants)
• Neural: Block itch signals (antihistamines, JAK inhibitors, nerve blocks)
• Behavioral: Habit reversal; replacing scratch response with alternative behaviors (ice application, light tap instead of scratch)
• Psychological: Address stress, anxiety, sleep deprivation which amplify itch

Patients who successfully manage chronic itch typically use combined approaches. Single interventions alone rarely suffice.

Itch in Dermatological Conditions: Context Matters

Atopic Dermatitis. The archetypal "itch that rashes." Filaggrin mutations compromise the skin barrier. Allergens and irritants penetrate deeply, activating mast cells and sensory nerves. First-line treatment is barrier repair (emollients) and anti-inflammatory (topical steroids). Newer agents (dupilumab, JAK inhibitors) target the underlying Th2 inflammation directly.

Psoriasis. Paradoxically less itchy than eczema despite visible inflammation. The itching that does occur is often associated with early lesions. Systemic treatments (TNF inhibitors, IL-17 inhibitors) work well. IL-23 inhibitors (newer) have exceptional efficacy.

Lichen Planus. An autoimmune condition causing violaceous bumps on wrists, genitals, or mouth. Intensely itchy. Topical steroids help; systemic steroids or retinoids for severe cases. The itch can persist for years even after lesions resolve (lichenoid dermatitis).

Urticaria. Acute hives from histamine release. Most resolve with antihistamines. For chronic urticaria (>6 weeks), omalizumab (anti-IgE) or cyclosporine often needed because the baseline histamine level is elevated.

Frequently Asked Questions

Q: Why does scratching feel so satisfying?
A: Scratching activates inhibitory spinal neurons that briefly block the itch signal from reaching the brain. The relief is real — but short-lived, because scratching also irritates the skin and re-triggers itch shortly afterward.

Q: Are itch and pain the same thing?
A: No. They were thought to be related, but research since 2007 has identified dedicated itch-specific neurons in the spinal cord (GRPR-positive). You can block itch without affecting pain, and vice versa.

Q: Why doesn't taking an antihistamine help my itch?
A: Probably because your itch isn't histamine-driven. Many itches — including those from chloroquine, opioids, dry skin, and nerve damage — use non-histamine pathways (Mrgpr receptors or neural mechanisms) that antihistamines can't touch.

Q: Why is itching contagious?
A: Visual centers and mirror neuron systems in the brain respond to seeing others scratch. Brain imaging shows the same itch-processing regions activate in observers even without any skin stimulus. It's a true centrally-generated itch.

Q: Is chronic itching a sign of something serious?
A: It can be. Persistent itch without an obvious skin cause warrants medical evaluation — liver disease, kidney disease, lymphoma, thyroid disease, and iron deficiency can all present as chronic itch.

Q: Why does dry skin itch so much?
A: A compromised skin barrier exposes nerve endings to environmental irritants and increases baseline firing of itch fibers. Moisturizers work because they restore the lipid barrier and reduce that baseline signal — often the single most effective intervention for everyday itch.

Chronic Itch as a Disorder

When itch persists for >6 weeks without resolution, it becomes chronic pruritus — a disorder in its own right. This isn't just "annoying"; chronic itch degrades quality of life as much as chronic pain.

Prevalence is higher than most realize: ~10% of the general population experiences chronic itch at some point. In dermatology clinics, it's one of the top three patient complaints. Yet it's historically been underfunded in research and undertreated.

Causes cluster into the four categories mentioned earlier, but treatment is often empirical — try A, if it fails try B. The GRPR pathway discovery has opened new doors. Drugs targeting GRPR (still in trials) could block itch signals without affecting pain or other nerve functions. For the first time, there's hope for itch-specific treatment rather than generic antihistamines.

Source: Stander, S., et al. (2023). "Clinical Classification of Itch." Acta Dermato-Venereologica 103, adv00835.

Advanced Treatment Strategies: Beyond Antihistamines

The revolution in itch treatment over the past decade goes far beyond antihistamines. Modern approaches target specific molecular pathways, recognizing that different itches require different strategies.

JAK Inhibitors. Janus kinase inhibitors (upadacitinib, abrocitinib, baricitinib) block inflammatory signaling downstream of IL-4 and IL-13. Unlike topical steroids, they can be applied directly to skin (topical ruxolitinib) or taken systemically. They work for atopic dermatitis, but also for inflammatory itches like lichen planus. The mechanism is cleaner than steroids — they target specific inflammation pathways rather than broadly suppressing immune function. However, JAK inhibitors carry a small risk of infections and thrombotic events, so they require monitoring.

TRPV1 Desensitization. Topical capsaicin works by activating TRPV1 channels on sensory neurons. Initially it causes burning, but repeated application desensitizes local nerve endings — they stop firing or respond at higher thresholds. This is particularly effective for neuropathic itch (post-shingles, brachioradial pruritus). Some patients need 4–8 weeks of application before relief kicks in.

Opioid Antagonists. Surprisingly, some itches involve opioid signaling — especially cholestatic itch from liver disease. Naltrexone, an opioid antagonist, can paradoxically relieve itch in these cases by blocking itch-promoting opioid pathways. The mechanism isn't fully understood, but it works in ~60% of cholestatic itch patients, compared to <20% for antihistamines.

Bile Acid Sequestrants. For cholestatic itch, cholestyramine and colesevelam bind bile acids in the GI tract and prevent reabsorption. This lowers bile acid levels in blood, which directly reduces itch. It's slow (takes weeks) and can interfere with absorption of other drugs, but it's one of the few treatments targeting the root cause rather than symptoms.

GRPR-Targeting Drugs. The most exciting frontier — drugs that directly block GRPR (the itch-specific neuron receptor) without touching pain. Compounds like MrgprX3 and NPPB antagonists are in trials. If successful, these will be the first itch-selective treatments in history.

Source: Simpson, E. L., et al. (2023). "Baricitinib vs Placebo and Dupilumab for Atopic Dermatitis." NEJM 389(16).

Itch in Different Diseases: Context Matters

Itch presents differently depending on the underlying disease, and this affects treatment strategy.

Atopic Dermatitis. The "itch that rashes" — a vicious cycle of inflammation and scratching. The skin barrier is compromised (mutations in filaggrin gene), allowing irritants in. Both antihistamines and JAK inhibitors work, but the key is early intervention and skin barrier repair (emollients). If scratching leads to infection, antibiotics are needed.

Psoriasis. Paradoxically, psoriasis is less itchy than eczema despite visible inflammation. The itch can be severe locally but often doesn't dominate the clinical picture. Topical corticosteroids work, but modern systemic treatments (TNF inhibitors, IL-17 inhibitors) work best.

Urticaria (hives). Sudden onset, usually histamine-driven. Antihistamines are first-line and effective in ~80% of cases. For antihistamine-refractory urticaria, add omalizumab (anti-IgE antibody) or cyclosporine.

Scabies. Caused by a mite burrowing into skin. Intense, stubborn itch. Requires antiparasitic treatment (permethrin cream, ivermectin) — antihistamines won't touch it.

Lymphoma and Malignancies. Paraneoplastic itch (itch caused by cancer, not invasion) can be severe and precedes diagnosis. Exact mechanism unknown. Treatment involves addressing the underlying cancer; supportive care includes emollients and JAK inhibitors.

Understanding disease context is crucial because the itch phenotype guides diagnosis backward.

Source: Ständer, S., & Weisshaar, E. (2015). "Evidence-Based Clinical Guide to Pruritus." Dermatology Practical & Conceptual 5(4).

The Evolutionary Mystery

Why do we have itch at all? Pain makes sense — it signals damage and drives avoidance. But itch is paradoxical: it drives scratching, which damages skin and can make infections worse. Some biologists argue itch evolved to detect parasites (mosquitoes, lice) and trigger removal before infestation spreads. But in modern indoor environments without parasites, itch is mostly a nuisance.

This mismatch between evolutionary origin and modern environment is common in biology — hay fever, food allergies, and inflammatory bowel disease are all oversensitivity of systems that evolved to protect us from parasites and pathogens.

Itch in the Brain and Psyche

Itch has a significant central (brain) component beyond the peripheral (skin) signal. Imaging studies show that chronic itch activates the anterior cingulate cortex (emotion), anterior insula (bodily sensation), and prefrontal cortex (decision-making). This suggests itch isn't just a sensory percept — it's emotionally amplified.

Itch and stress. Psychological stress exacerbates itch in eczema, psoriasis, and other conditions. The mechanism likely involves cortisol suppressing immune function and the hypothalamic-pituitary-adrenal axis modulating itch neurotransmitters. Stress-management interventions (CBT, mindfulness) have proven effective for some patients.

Itch and depression. Chronic itch and depression are bidirectional — itch causes depression from loss of sleep and constant distraction; depression worsens itch by reducing pain threshold and amplifying symptom perception. Antidepressants (SSRIs, SNRIs) can help some patients, not just by treating depression but by modulating pain/itch-related neurotransmitters like serotonin and norepinephrine.

Psychogenic itch. Pure psychological itch exists, though it's rare as a primary diagnosis. Delusional parasitosis (the fixed conviction that one is infested with bugs despite no evidence) causes patients to scratch until they cause open wounds. These patients need psychiatric treatment (antipsychotics) more than dermatological cream.

Source: Pfab, F., et al. (2016). "Psychosomatic Aspects of Itch." Journal of Dermatological Treatment 27(3).

Itch Management in Clinical Practice

The practical approach dermatologists use combines triage (type classification), investigation, and stepped treatment.

Step 1: Hydration and Barrier Repair. For dry skin itches (extremely common), aggressive moisturizing is first-line. Ceramide-rich creams work better than lightweight lotions because they restore lipid layers in the stratum corneum.

Step 2: Identify and Avoid Triggers. If contact dermatitis, stop using the offending agent (nickel jewelry, latex gloves, fragrance). If atopy, work with allergy/immunology. If drug-induced (ACE inhibitors, opioids), consider switching.

Step 3: Anti-Inflammatory. Topical steroids or calcineurin inhibitors for eczema/dermatitis. Oral antihistamines for histamine-driven itch (urticaria, allergic rhinitis).

Step 4: Escalate if Needed. If steps 1–3 fail, add systemic agents: JAK inhibitors, dupilumab, cyclosporine, or naltrexone depending on diagnosis.

Step 5: Specialist Referral. Refractory itch may need rheumatology (autoimmune), gastroenterology (liver disease), or psychiatry (psychogenic/psychosomatic).

This stepped approach ensures most patients find relief while minimizing unnecessary medication exposure.

---

Read next:

• How the Skin Works — Largest Organ in the Body
• How the Immune System Defends the Body
• How the Nervous System Works — Brain, Spinal Cord, Nerves

Sources

• Sun, Y. G. & Chen, Z. F. (2007). "A gastrin-releasing peptide receptor mediates the itch sensation in the spinal cord." Nature.
• Han, L., et al. (2013). "A subpopulation of nociceptors specifically linked to itch." Nature Neuroscience.
• Davidson, S., et al. (2009). Scratching and spinal inhibition of itch, Journal of Neuroscience.
• Holle, H., et al. (2012). "Neural basis of contagious itch." PNAS.
• Cochrane review of dupilumab and JAK inhibitors for atopic dermatitis (2020+).